Brief: Simcere Pharmaceutical Says Publication By New England Journal Of Medicine For COVID-19 Drug
18/01/2024 12:51
Jan 18 (Reuters) - Simcere Pharmaceutical Group Ltd
2096.HK :
* SIMCERE PHARMACEUTICAL - PUBLICATION BY NEW ENGLAND
JOURNAL OF
MEDICINE OF PHASE II/III CLINICAL STUDIES RESULTS OF XIANNUOXIN
FOR COVID-19
Further company coverage: 2096.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Simcere Pharmaceutical
See all newsBrief: Simcere Pharmaceutical Announces Approval For Marketing Of Yingmule In China By NMPA
Simcere Pharmaceutical jumps most in two months on Roche tie-up
Roche signs global licensing pact for Simcere's experimental blood cancer drug (updated)
Roche signs global licensing pact for Simcere's B-cell cancer drug candidate
Brief: Simcere Pharmaceutical Enters Exclusive Global Licensing Agreement With Roche For SIM0660